JSJayla Lynn Scott

Jayla Lynn Scott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jayla Lynn Scott has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Risk factors for antepartum venous thromboembolism in pregnant people with sickle cell disease

    by Gloria F. Gerber, Sacha Choupa, Amy Luo, Vinal Menon, Nadine Shehata, Jayla Scott, Macy L. E. Gatti, Michael B. Streiff, Rakhi P. Naik, Kevin Kuo, et al.

    Summary: Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.

  • A young adult clinic to support integration into adult sickle cell disease care: If you build it, they will come

    by Elizabeth J. Prince, Jayla L. Scott, Ogechi Nwankwoala, Lystra Ali‐Houchens, M. Amir Alghali, C. Patrick Carroll, Sophie Lanzkron, Lydia H. Pecker

    Summary: In high‐income countries, individuals with sickle cell disease (SCD) almost universally survive into adulthood, but transfer to adult SCD care is fraught. The young adult clinic (YAC) at our sickle cell centre was designed to provide developmentally appropriate, expert SCD care to young adults with SCD aged 18–30 years. In this retrospective cohort study, we measured YAC appointment attendance and scheduling attempts based on patient referral source and demographic characteristics. Between 1 March 2019 and 30 September 2023, 89% (170/192) of referred patients attended a YAC appointment, and 97% (77/79) of patients referred from paediatric SCD care attended a YAC appointment. Most patients attended their first scheduled appointment (61%, 105/170). Among rescheduled patients, the mean number of scheduling attempts before attendance was 2.9 (standard deviation 1.5). During the 55‐month study period, this cohort had five deaths (3%) and seven successful haematopoietic stem cell transplants (4%). These results indicate that healthcare systems designed to meet the needs of young adults with SCD enable successful participation in adult SCD care. Resources to build robust adult SCD care systems are desperately needed, alongside research regarding optimal approaches to integrating young people into adult SCD care.


  • Open Access

    Variability in Notification of Positive Newborn Screening Results for Sickle Cell Trait Across the United States

    by Jayla Lynn Scott, Jana Christian, Manuela Plazas Montana, Yvette M. Miller, Rakhi P. Naik

    Universal in the United States (US) since 2006, newborn screening (NBS) programs for sickle cell disease (SCD) allow for early identification of the disease and, as an unintentional byproduct, identification of sickle cell trait (SCT). Unlike other carrier states, SCT is highly prevalent and is found in nearly 3 million Americans, which results in important reproductive implications. Currently, all NBS programs in the US are responsible for their own policies regarding SCT notification, and little is known about how SCT notification practices are performed and how these practices vary across NBS programs. We surveyed NBS programs personnel in all 50 states, the District of Columbia, and the US’ territories of Puerto Rico and Guam (n = 53) using an electronic survey. There was a 100% response rate. All NBS programs (100%) provide notification of SCT status to either a pediatrician or parent: 49% notify the pediatrician only, 45% notify both the pediatrician and parent, and 6% notify the parent only. A total of 98% of NBS programs retain electronic records of SCT status, but only 38% can be directly accessed by pediatricians/primary care doctors. No state operates a publicly available database that allows individuals to access their own records. Only one state provides renotification at reproductive age. In conclusion, there is wide variability in NBS practices for SCT notification. This study demonstrates a need for national guidelines to standardize SCT notification across the US to ensure effective notification and counseling for SCT.